YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- Dutch engineering and consultancy group Arcadis (AS:ARDS) set targets for mid-single-digit organic revenue growth and long term profitability on Tuesday, while also announcing plans to streamline its portfolio and reduce o…
The growth of the pneumonia market is expected to be primarily driven by an expanding patient population and advancements in diagnostic methods. Additionally, the expected launch of emerging therapies such as Tosatoxumab (AR-301) (Aridis P…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
Investing.com - KeyBanc has reduced its price target on Arcadis (AS:ARDS) NV (AS:ARCAD) to €52.00 from €55.00 while maintaining an Overweight rating on the engineering and consulting firm’s stock. The adjustment follows virtual meetings be…
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a bi…
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections,…
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single confirmatory Phase 3 study of inve…
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of no…
LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development o…
LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infectio…
LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibo…
LOS GATOS, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (the “Notice”) from the Listing Qualificati…
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (the “Notice”) from the Listing Qualifica…
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments. The Company received wri…
Los Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,…
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Aridis P…
The Cystic Fibrosis Foundation is spinning some of the half-billion dollars it received as part of a royalty deal in 2016 into Bay Area companies looking at ways to tackle persistent infections and perhaps even mutation-fixing cures. Conti…
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational mo…
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, In…
Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections,…
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms unde…
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms unde…
The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Aridis…
Los Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infectio…
The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readoutwill be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals,…
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutica…
DICE Therapeutics DICE skyrocketed 62.27% on Oct 11 after the company announced positive top-line data from a phase I study evaluating its lead therapeutic candidate, DC-806, for treating psoriasis. Shares of DICE Therapeutics have surged…
scPharmaceuticals SCPH recently announced that the FDA approved its proprietary formulation of furosemide in 80 mg dosage delivered via an on-body infusor, marketed under the trade name Furoscix (furosemide injection) for treating congesti…
Iovance Biotherapeutics IOVA recently announced that the first patient had been dosed in phase I/II IOV-GM1-201 study, evaluating the company’s genetically modified, tumor-infiltrating lymphocyte (TIL) therapy, IOV-4001 in patients with pr…
Shares of Wave Lifesciences WVE were up 8.26% on Sep 20, after the company announced a positive update from its ongoing phase Ib/IIa SELECT-HD study on its clinical candidate, WVE-009 for treating Huntington’s disease (HD). Wave Therapeuti…
Intellia Therapeutics NTLA and its partner Regeneron Pharmaceuticals REGN recently announced positive interim results from an ongoing phase I study of its lead candidate NTLA-2001. The candidate is being developed as a single-dose treatmen…
bluebird bio BLUE recently received accelerated FDA approval for Syskona (elivaldogene autotemcel), also known as eli-cel, as a treatment for patients less than 18 years of age with early, active cerebral adrenoleukodystrophy (CALD). Upon…
Pfizer PFE announced that it had submitted a new drug application (“NDA”) to the FDA seeking approval for an oral antiviral pill for COVID-19, Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The NDA seeks approval for…
Shares of Endo International Plc ENDP crashed 26% on Jun 29, right after the pharma stock witnessed a surge the day before. Endo is knee-deep in trouble with several litigation suits over opioid sales that have caused shares to underperfor…
Good morning, investor! We’ve reached the halfway point of the week and we’re starting it with an overview of the biggest pre-market stock movers for Wednesday! A close-up shot of the Wall Street street sign representing Pre-Market Stock M…
Carnival (NYSE:CCL) stock is sailing higher on Tuesday and there’s several reasons why that investors need to know about. Carnival (CCL stock) cruise ship on water in front of beach with chairs Source: Flickr Let’s dive into all the news b…